Most pediatric patients with Sjögren’s disease displayed an interferon signature in their blood and parotid gland tissue, which could help confirm diagnoses and shorten treatment delays, according to data presented at EULAR 2024 Congress.
“This can actually be used and introduced in clinical practice, not only in patients with Sjögren’s syndrome but also in children, actually, as a new diagnostic test,” Dirk Foell, MD, chair of the EULAR pediatric rheumatology committee, said during a press conference at the meeting. “That’s a major advancement.”
The data